title: Newer positron emission tomography radiopharmaceuticals for radiotherapy planning: an overview.
abstract: Positron emission tomography-computed tomography (PET-CT) has changed cancer imaging in the last decade, for better. It can be employed for radiation treatment planning of different cancers with improved accuracy and outcomes as compared to conventional imaging methods. (18)F-fluorodeoxyglucose remains the most widely used though relatively non-specific cancer imaging PET tracer. A wide array of newer PET radiopharmaceuticals has been developed for targeted imaging of different cancers. PET-CT with such new PET radiopharmaceuticals has also been used for radiotherapy planning with encouraging results. In the present review we have briefly outlined the role of PET-CT with newer radiopharmaceuticals for radiotherapy planning and briefly reviewed the available literature in this regard.
authors.affiliation: 1 Department of Nuclear Medicine and PET-CT, Apollo Gleneagles Hospitals, Kolkata, India ; 2 Department of Nuclear Medicine and PET-CT, Eastern Diagnostics India Ltd., Kolkata, India.
authors.forename: Punit
authors.initials: P
authors.lastname: Sharma
authors.affiliation: 1 Department of Nuclear Medicine and PET-CT, Apollo Gleneagles Hospitals, Kolkata, India ; 2 Department of Nuclear Medicine and PET-CT, Eastern Diagnostics India Ltd., Kolkata, India.
authors.forename: Anirban
authors.initials: A
authors.lastname: Mukherjee
keywords: 11C-choline; 11C-methionine; 18F-FMISO; PET-computed tomography (PET-CT); Positron emission tomography (PET); radiotherapy planning